Sareum to present at major research congress in China

(AIM: SAR)   25 October 2010
 
SAREUM HOLDINGS PLC
 
                          ("Sareum" or the "Company")
 
             Sareum to Present at Major Research Congress in China
Sareum  (AIM: SAR), the specialist cancer drug discovery business, is pleased to
announce  that  Dr  Tim  Mitchell,  CEO,  and  Dr John Reader, CSO, will present
Sareum's cancer research programmes and SKIL drug discovery platform at the 8th
International  Drug  Discovery  Sciences  and  Technology  (IDDST)  Congress  in
Beijing, China.
 
Today,  Dr Mitchell will present Sareum's SKIL platform at the session focussing
on  new kinase  inhibitors. Tomorrow  (Oct 26), Dr  Reader will present Sareum's
Chk-1 and  VEGFR-3 cancer  research  programmes  at  the  symposium dedicated to
cancer drug discovery.
 
Sareum's  CEO, Dr Tim  Mitchell, commented: "China  is set to  become one of the
major forces in bio-science innovation. This is a significant opportunity for us
to  showcase our drug research programmes and the technology behind them at this
prestigious  congress, as well  as at the  many company meetings  that will take
place after the event.
 
 Sareum Holdings plc
 
 Tim Mitchell                 01223 497 700
 
Merchant Securities Limited (Nomad)
 
 Simon Clements/Bidhi Bhoma   020 7628 2200
 
Hybridan LLP (Broker)
 
 Claire Noyce                 020 7947 4350
 
Notes for editors:
 
About Sareum Holdings plc
Sareum  is  a  drug  discovery  company,  headquartered in Cambridge UK, that is
focused  on  producing  targeted  small  molecule  therapeutics to address unmet
medical  needs, primarily  in cancer.  Sareum aims  to successfully deliver drug
candidates  for licensing to  pharmaceutical and biotechnology  companies at the
pre-clinical or early clinical trials stage.
 
Sareum's Chk1 kinase cancer research programme is a joint research collaboration
with  The Institute of  Cancer Research and  Cancer Research Technology Limited.
Novel  chemical  compounds  developed  by  the  collaboration have been shown to
increase  the  effectiveness  of  current  cancer therapeutics in in-vivo cancer
models.
 
SKIL®  (Sareum Kinase Inhibitor  Library) is Sareum's  drug discovery technology
platform  that has  so far  produced the  Company's Aurora, VEGFR-3, FLT3 & TYK2
kinase  cancer  and  auto-immune  disease  research  programmes.  SKIL  can also
generate drug research programmes against other kinase targets.
 
Sareum  Holdings  plc  joined  the  AIM  market  of the London Stock Exchange in
October  2004, trading under  the symbol  SAR.  For  further information, please
visit www.sareum.co.uk
 
[HUG#1454610]
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: SAREUM HOLDINGS PLC via Thomson Reuters ONE